Bayer "virtual walk" benefits hemophilia group

Share this article:
Bayer "virtual walk" benefits hemophilia group
Bayer "virtual walk" benefits hemophilia group
Bayer HealthCare Pharmaceuticals is holding a “virtual walk” for the National Hemophilia Foundation (NHF) and its local chapters. The company will sponsor walkers to the tune of up to $60,000.

A Bayer spokesperson said the campaign complements NHF's real walks, and has garnered over 850 signatures in the ten days since its launch, timed to coincide with World Hemophilia Day on April 17 (the company's Bay Area-based US unit took part in an April 16 5K walk in Berkeley to mark the occasion).

Participants in the virtual walk can create a virtual character at walkforhemophilia.com, choose a message and select a local NHF chapter to walk for. The to pthree chapters with the most virtual walkers by November 6 will receive $15,000, $10,000 and $5,000 in sponsorship funds, respectively, while the national office will get up to $30,000. Signatories are prompted to share the event with friends and family via Facebook, Twitter or email.

Paul Bedard, VP/General Manager for hematology at Bayer, said in a statement: “The Virtual Walk for Hemophilia is the latest in a series of innovative programs and services, such as FactorTrack, a mobile application to help track and record infusions for people with bleeding disorders, including those with hemophilia A.”

The company's Consumer Care unit has previously sponsored virtual marches for breast cancer research in support of its One a Day women's multivitamin franchise.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...